VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.

Commercial Capabilities One Pager

October 2, 2026
Explore how OXB helps cell and gene therapy developers navigate the path to commercial supply with expertise spanning process characterisation, PPQ, regulatory support and commercial-scale GMP manufacturing. Discover our proven late-stage experience, global manufacturing network and end-to-end capabilities designed to de-risk commercialisation and accelerate programme readiness.
View Resource